Health care

Subterms

    More stories

    • 138 Shares169 Views

      in Data Management & Statistics

      The promise and pitfalls of artificial intelligence explored at TEDxMIT event

      by

      Scientists, students, and community members came together last month to discuss the promise and pitfalls of artificial intelligence at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) for the fourth TEDxMIT event held at MIT. 

      Attendees were entertained and challenged as they explored “the good and bad of computing,” explained CSAIL Director Professor Daniela Rus, who organized the event with John Werner, an MIT fellow and managing director of Link Ventures; MIT sophomore Lucy Zhao; and grad student Jessica Karaguesian. “As you listen to the talks today,” Rus told the audience, “consider how our world is made better by AI, and also our intrinsic responsibilities for ensuring that the technology is deployed for the greater good.”

      Rus mentioned some new capabilities that could be enabled by AI: an automated personal assistant that could monitor your sleep phases and wake you at the optimal time, as well as on-body sensors that monitor everything from your posture to your digestive system. “Intelligent assistance can help empower and augment our lives. But these intriguing possibilities should only be pursued if we can simultaneously resolve the challenges that these technologies bring,” said Rus. 

      The next speaker, CSAIL principal investigator and professor of electrical engineering and computer science Manolis Kellis, started off by suggesting what sounded like an unattainable goal — using AI to “put an end to evolution as we know it.” Looking at it from a computer science perspective, he said, what we call evolution is basically a brute force search. “You’re just exploring all of the search space, creating billions of copies of every one of your programs, and just letting them fight against each other. This is just brutal. And it’s also completely slow. It took us billions of years to get here.” Might it be possible, he asked, to speed up evolution and make it less messy?

      The answer, Kellis said, is that we can do better, and that we’re already doing better: “We’re not killing people like Sparta used to, throwing the weaklings off the mountain. We are truly saving diversity.”

      Knowledge, moreover, is now being widely shared, passed on “horizontally” through accessible information sources, he noted, rather than “vertically,” from parent to offspring. “I would like to argue that competition in the human species has been replaced by collaboration. Despite having a fixed cognitive hardware, we have software upgrades that are enabled by culture, by the 20 years that our children spend in school to fill their brains with everything that humanity has learned, regardless of which family came up with it. This is the secret of our great acceleration” — the fact that human advancement in recent centuries has vastly out-clipped evolution’s sluggish pace.

      The next step, Kellis said, is to harness insights about evolution in order to combat an individual’s genetic susceptibility to disease. “Our current approach is simply insufficient,” he added. “We’re treating manifestations of disease, not the causes of disease.” A key element in his lab’s ambitious strategy to transform medicine is to identify “the causal pathways through which genetic predisposition manifests. It’s only by understanding these pathways that we can truly manipulate disease causation and reverse the disease circuitry.” 

      Kellis was followed by Aleksander Madry, MIT professor of electrical engineering and computer science and CSAIL principal investigator, who told the crowd, “progress in AI is happening, and it’s happening fast.” Computer programs can routinely beat humans in games like chess, poker, and Go. So should we be worried about AI surpassing humans? 

      Madry, for one, is not afraid — or at least not yet. And some of that reassurance stems from research that has led him to the following conclusion: Despite its considerable success, AI, especially in the form of machine learning, is lazy. “Think about being lazy as this kind of smart student who doesn’t really want to study for an exam. Instead, what he does is just study all the past years’ exams and just look for patterns. Instead of trying to actually learn, he just tries to pass the test. And this is exactly the same way in which current AI is lazy.”

      A machine-learning model might recognize grazing sheep, for instance, simply by picking out pictures that have green grass in them. If a model is trained to identify fish from photos of anglers proudly displaying their catches, Madry explained, “the model figures out that if there’s a human holding something in the picture, I will just classify it as a fish.” The consequences can be more serious for an AI model intended to pick out malignant tumors. If the model is trained on images containing rulers that indicate the size of tumors, the model may end up selecting only those photos that have rulers in them.

      This leads to Madry’s biggest concerns about AI in its present form. “AI is beating us now,” he noted. “But the way it does it [involves] a little bit of cheating.” He fears that we will apply AI “in some way in which this mismatch between what the model actually does versus what we think it does will have some catastrophic consequences.” People relying on AI, especially in potentially life-or-death situations, need to be much more mindful of its current limitations, Madry cautioned.

      There were 10 speakers altogether, and the last to take the stage was MIT associate professor of electrical engineering and computer science and CSAIL principal investigator Marzyeh Ghassemi, who laid out her vision for how AI could best contribute to general health and well-being. But in order for that to happen, its models must be trained on accurate, diverse, and unbiased medical data.

      It’s important to focus on the data, Ghassemi stressed, because these models are learning from us. “Since our data is human-generated … a neural network is learning how to practice from a doctor. But doctors are human, and humans make mistakes. And if a human makes a mistake, and we train an AI from that, the AI will, too. Garbage in, garbage out. But it’s not like the garbage is distributed equally.”

      She pointed out that many subgroups receive worse care from medical practitioners, and members of these subgroups die from certain conditions at disproportionately high rates. This is an area, Ghassemi said, “where AI can actually help. This is something we can fix.” Her group is developing machine-learning models that are robust, private, and fair. What’s holding them back is neither algorithms nor GPUs. It’s data. Once we collect reliable data from diverse sources, Ghassemi added, we might start reaping the benefits that AI can bring to the realm of health care.

      In addition to CSAIL speakers, there were talks from members across MIT’s Institute for Data, Systems, and Society; the MIT Mobility Initiative; the MIT Media Lab; and the SENSEable City Lab.

      The proceedings concluded on that hopeful note. Rus and Werner then thanked everyone for coming. “Please continue to reflect about the good and bad of computing,” Rus urged. “And we look forward to seeing you back here in May for the next TEDxMIT event.”

      The exact theme of the spring 2022 gathering will have something to do with “superpowers.” But — if December’s mind-bending presentations were any indication — the May offering is almost certain to give its attendees plenty to think about. And maybe provide the inspiration for a startup or two. More

    • 63 Shares149 Views

      in Data Management & Statistics

      Meet the 2021-22 Accenture Fellows

      by

      Launched in October of 2020, the MIT and Accenture Convergence Initiative for Industry and Technology underscores the ways in which industry and technology come together to spur innovation. The five-year initiative aims to achieve its mission through research, education, and fellowships. To that end, Accenture has once again awarded five annual fellowships to MIT graduate students working on research in industry and technology convergence who are underrepresented, including by race, ethnicity, and gender.

      This year’s Accenture Fellows work across disciplines including robotics, manufacturing, artificial intelligence, and biomedicine. Their research covers a wide array of subjects, including: advancing manufacturing through computational design, with the potential to benefit global vaccine production; designing low-energy robotics for both consumer electronics and the aerospace industry; developing robotics and machine learning systems that may aid the elderly in their homes; and creating ingestible biomedical devices that can help gather medical data from inside a patient’s body.

      Student nominations from each unit within the School of Engineering, as well as from the four other MIT schools and the MIT Schwarzman College of Computing, were invited as part of the application process. Five exceptional students were selected as fellows in the initiative’s second year.

      Xinming (Lily) Liu is a PhD student in operations research at MIT Sloan School of Management. Her work is focused on behavioral and data-driven operations for social good, incorporating human behaviors into traditional optimization models, designing incentives, and analyzing real-world data. Her current research looks at the convergence of social media, digital platforms, and agriculture, with particular attention to expanding technological equity and economic opportunity in developing countries. Liu earned her BS from Cornell University, with a double major in operations research and computer science.

      Caris Moses is a PhD student in electrical engineering and computer science specializing inartificial intelligence. Moses’ research focuses on using machine learning, optimization, and electromechanical engineering to build robotics systems that are robust, flexible, intelligent, and can learn on the job. The technology she is developing holds promise for industries including flexible, small-batch manufacturing; robots to assist the elderly in their households; and warehouse management and fulfillment. Moses earned her BS in mechanical engineering from Cornell University and her MS in computer science from Northeastern University.

      Sergio Rodriguez Aponte is a PhD student in biological engineering. He is working on the convergence of computational design and manufacturing practices, which have the potential to impact industries such as biopharmaceuticals, food, and wellness/nutrition. His current research aims to develop strategies for applying computational tools, such as multiscale modeling and machine learning, to the design and production of manufacturable and accessible vaccine candidates that could eventually be available globally. Rodriguez Aponte earned his BS in industrial biotechnology from the University of Puerto Rico at Mayaguez.

      Soumya Sudhakar SM ’20 is a PhD student in aeronautics and astronautics. Her work is focused on theco-design of new algorithms and integrated circuits for autonomous low-energy robotics that could have novel applications in aerospace and consumer electronics. Her contributions bring together the emerging robotics industry, integrated circuits industry, aerospace industry, and consumer electronics industry. Sudhakar earned her BSE in mechanical and aerospace engineering from Princeton University and her MS in aeronautics and astronautics from MIT.

      So-Yoon Yang is a PhD student in electrical engineering and computer science. Her work on the development of low-power, wireless, ingestible biomedical devices for health care is at the intersection of the medical device, integrated circuit, artificial intelligence, and pharmaceutical fields. Currently, the majority of wireless biomedical devices can only provide a limited range of medical data measured from outside the body. Ingestible devices hold promise for the next generation of personal health care because they do not require surgical implantation, can be useful for detecting physiological and pathophysiological signals, and can also function as therapeutic alternatives when treatment cannot be done externally. Yang earned her BS in electrical and computer engineering from Seoul National University in South Korea and her MS in electrical engineering from Caltech. More

    • 100 Shares99 Views

      in Data Management & Statistics

      Enabling AI-driven health advances without sacrificing patient privacy

      by

      There’s a lot of excitement at the intersection of artificial intelligence and health care. AI has already been used to improve disease treatment and detection, discover promising new drugs, identify links between genes and diseases, and more.

      By analyzing large datasets and finding patterns, virtually any new algorithm has the potential to help patients — AI researchers just need access to the right data to train and test those algorithms. Hospitals, understandably, are hesitant to share sensitive patient information with research teams. When they do share data, it’s difficult to verify that researchers are only using the data they need and deleting it after they’re done.

      Secure AI Labs (SAIL) is addressing those problems with a technology that lets AI algorithms run on encrypted datasets that never leave the data owner’s system. Health care organizations can control how their datasets are used, while researchers can protect the confidentiality of their models and search queries. Neither party needs to see the data or the model to collaborate.

      SAIL’s platform can also combine data from multiple sources, creating rich insights that fuel more effective algorithms.

      “You shouldn’t have to schmooze with hospital executives for five years before you can run your machine learning algorithm,” says SAIL co-founder and MIT Professor Manolis Kellis, who co-founded the company with CEO Anne Kim ’16, SM ’17. “Our goal is to help patients, to help machine learning scientists, and to create new therapeutics. We want new algorithms — the best algorithms — to be applied to the biggest possible data set.”

      SAIL has already partnered with hospitals and life science companies to unlock anonymized data for researchers. In the next year, the company hopes to be working with about half of the top 50 academic medical centers in the country.

      Unleashing AI’s full potential

      As an undergraduate at MIT studying computer science and molecular biology, Kim worked with researchers in the Computer Science and Artificial Intelligence Laboratory (CSAIL) to analyze data from clinical trials, gene association studies, hospital intensive care units, and more.

      “I realized there is something severely broken in data sharing, whether it was hospitals using hard drives, ancient file transfer protocol, or even sending stuff in the mail,” Kim says. “It was all just not well-tracked.”

      Kellis, who is also a member of the Broad Institute of MIT and Harvard, has spent years establishing partnerships with hospitals and consortia across a range of diseases including cancers, heart disease, schizophrenia, and obesity. He knew that smaller research teams would struggle to get access to the same data his lab was working with.

      In 2017, Kellis and Kim decided to commercialize technology they were developing to allow AI algorithms to run on encrypted data.

      In the summer of 2018, Kim participated in the delta v startup accelerator run by the Martin Trust Center for MIT Entrepreneurship. The founders also received support from the Sandbox Innovation Fund and the Venture Mentoring Service, and made various early connections through their MIT network.

      To participate in SAIL’s program, hospitals and other health care organizations make parts of their data available to researchers by setting up a node behind their firewall. SAIL then sends encrypted algorithms to the servers where the datasets reside in a process called federated learning. The algorithms crunch the data locally in each server and transmit the results back to a central model, which updates itself. No one — not the researchers, the data owners, or even SAIL —has access to the models or the datasets.

      The approach allows a much broader set of researchers to apply their models to large datasets. To further engage the research community, Kellis’ lab at MIT has begun holding competitions in which it gives access to datasets in areas like protein function and gene expression, and challenges researchers to predict results.

      “We invite machine learning researchers to come and train on last year’s data and predict this year’s data,” says Kellis. “If we see there’s a new type of algorithm that is performing best in these community-level assessments, people can adopt it locally at many different institutions and level the playing field. So, the only thing that matters is the quality of your algorithm rather than the power of your connections.”

      By enabling a large number of datasets to be anonymized into aggregate insights, SAIL’s technology also allows researchers to study rare diseases, in which small pools of relevant patient data are often spread out among many institutions. That has historically made the data difficult to apply AI models to.

      “We’re hoping that all of these datasets will eventually be open,” Kellis says. “We can cut across all the silos and enable a new era where every patient with every rare disorder across the entire world can come together in a single keystroke to analyze data.”

      Enabling the medicine of the future

      To work with large amounts of data around specific diseases, SAIL has increasingly sought to partner with patient associations and consortia of health care groups, including an international health care consulting company and the Kidney Cancer Association. The partnerships also align SAIL with patients, the group they’re most trying to help.

      Overall, the founders are happy to see SAIL solving problems they faced in their labs for researchers around the world.

      “The right place to solve this is not an academic project. The right place to solve this is in industry, where we can provide a platform not just for my lab but for any researcher,” Kellis says. “It’s about creating an ecosystem of academia, researchers, pharma, biotech, and hospital partners. I think it’s the blending all of these different areas that will make that vision of medicine of the future become a reality.” More